Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2026)

Caris Life Sciences' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $525.3 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $525.3 million; the TTM figure through Mar 2026 stood at $525.3 million (changed N/A YoY), while the FY2025 annual figure was $506.0 million, down 4.4% from the prior year.
• Total Non-Current Liabilities was $525.3 million for Q1 2026 at Caris Life Sciences, up from $506.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $529.3 million in Q4 2024 to a low of $502.2 million in Q2 2025.
• Historically, Total Non-Current Liabilities has averaged $513.8 million across 3 years, with a median of $506.2 million in 2025.
• Biggest YoY gain for Total Non-Current Liabilities was 4.4% in 2025; the steepest drop was 4.4% in 2025.
• A 3-year view of Total Non-Current Liabilities shows it stood at $529.3 million in 2024, then declined by 4.4% to $506.0 million in 2025, then gained by 3.82% to $525.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $525.3 million (Q1 2026), $506.0 million (Q4 2025), and $506.2 million (Q3 2025), per Business Quant data.